Global Cancer Biomarkers Market – Industry Trends & Forecast to 2026

SUBSCRIBE FOR UPDATED REPORTS

Get great contents delivered straight to your inbox everyday, just a click away, Sign Up Now.
Name
Email
US : +1-888-387-2818
UK : +44 208 089 1725

Global Cancer Biomarkers Market – Industry Trends & Forecast to 2026

Global
Upcoming Reports
Global Cancer Biomarkers Market
  • No of pages :
    350
  • No of Figures:
    60
  • No of Tables:
    220
  • Report Type:
    Upcoming
  • Category:

Global Cancer Biomarkers Market By Type (genetic biomarkers, protein biomarkers, other cancer biomarkers) cancer type (breast cancer, lung cancer, prostate cancer, colorectal cancer , blood cancer, melanoma , ovarian cancer, liver cancer, stomach cancer, other cancer types ), technology ( imaging technologies, omic technologies (proteomics, genomics, other omic technologies), cytogenetics-based tests, immunoassays), applications  (drug discovery and development, personalized medicine, diagnostics, others), Geography (North America, South America, Europe, Asia-Pacific andMiddle East and Africa) – Industry Trends & Forecast to 2026

Market Analysis: Global Cancer Biomarkers Market

Global Cancer Biomarkers Market is expected to rise from its initial estimated value of USD 21.85 billion in 2018 to an estimated value of USD 56.06 billion by 2026, registering a CAGR of 12.5% in the forecast period of 2019-2026. This rise in market value can be attributed to the increasing Use of Cancer Biomarkers in Drug Discovery and Development.

Market Definition: Global Cancer Biomarkers Market

Cancer biomarkers are the molecules secreted by a tumor or a specific response of the human body indicating the presence of cancer. The biomarkers enable cancer detection at an early stage and facilitate high-speed noninvasive diagnosis using various genomics and proteomics tools. Cancer biomarkers are used for various applications such as cancer diagnostics, drug discovery and development, prognostics, personalized medicine, and surrogate endpoints. Over the years, cancer biomarkers have become an integral part of research in pharmaceutical and clinical trial companies, as they help to reduce the time and cost of the drug discovery and development process.

According to World Health Organization, there were an estimated 9.6 million deaths in 2018 due to cancer; Cancer is the second leading cause of death globally. About 1 in 6 deaths is due to cancer. These deaths could have been avoided with the availability of proper medical equipment and devices for healthcare procedures. This significant number is expected to act as a driver to the market growth

Market Drivers

  • Rising incidence of cancer is working as a market driver for this market
  • Increasing use of cancer biomarkers in drug discovery and development due to its ease of use and accurate results.
  • Due to increase in cancer cases there is increase in demand for Biomarkers

Market Restraints

  • Unfavorable regulatory and reimbursement scenario due to high cancer case regulatory has made strict norms.
  • High capital investment is required for biomarker but benefit is low as compared to cost-
  • Technical issues  is very high at the time of  sample collection and storage this is working as a market restraint.

Segmentation: Global Cancer Biomarkers Market

  • By Type
    • Genetic Biomarkers
    • Protein Biomarkers
    • Other Cancer Biomarkers
  • By Cancer Type
    • Breast Cancer
    • Lung Cancer
    • Prostate Cancer
    • Colorectal Cancer
    • Blood Cancer
    • Melanoma
    • Ovarian Cancer
    • Liver Cancer
    • Stomach Cancer
    • Other Cancer Types
  • By Technology
    • Imaging technologies
    • Omic Technologies
      • Proteomics
      • Genomics
      • Other Omic technologies
    • Cytogenetics-Based Tests
    • Immunoassays
  • By Applications
    • Drug discovery and Development
    • Personalized medicine
    • Diagnostics
    • Others
  • By Geography
    • North America
      • US.
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Rest of South America
    • Europe
      • Germany
      • France
      • United Kingdom
      • Italy
      • Spain
      • Russia
      • Turkey
      • Belgium
      • Netherlands
      • Switzerland
      • Rest of Europe
    • Asia-Pacific
      • Japan
      • China
      • South Korea
      • India
      • Australia
      • Singapore
      • Thailand
      • Malaysia
      • Indonesia
      • Philippines
      • Rest of Asia Pacific
    • Middle East & Africa
      • South Africa
      • Egypt
      • Saudi Arabia
      • United Arab Emirates
      • Israel
      • Rest of Middle East & Africa

Key Developments in the Market:

  • In April 2019, the University of Otago, New Zealand, and the Indian Statistical Institute (ISI), India have discovered epigenetic markers that aredistinctly different in oral cancer tissues This phenomenon is new and focused on oral cancer particularly.
  • In April 2019, Princess Margaret Cancer Centre in Toronto, Canada, has combined liquid biopsy, epigenetic alterations and machine learning to develop a blood test to detect and classify cancer at its earliest stages. This will change the usage of Biomarkers in cancer Market so that cancer can be identified in its initial stages.

Competitive Analysis: Global Cancer Biomarkers Market

Global cancer biomarkers market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of cancer biomarkers market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Market Competitors: Global Cancer Biomarkers Market

Few of the major competitors currently working in the Cancer Biomarkers market are Abbott (U.S), DiagnoCure Inc ( Canada)., Affymetrix, Inc. (U.S), Illumina, Inc.(U.S.) , QIAGEN. (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies Inc. (U.S.) , Quest Diagnostics Inc. (U.S.), Merck & Co. Inc. (U.S.) , Hologic, Inc ( U.S)., BD (U.S.) GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Bristol-Myers Squibb (US), Eli Lilly and Company (US), Pfizer, Inc. (US), and Genomic Health, Inc. (US), bioMérieux SA (France), Astellas Pharma Inc. (Japan), Myriad Genetics (US), Epigenomics AG (Germany) and Radient Pharmaceuticals(Bangladesh) . and Company among others.

Research Methodology: Global Cancer Biomarkers Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request an Analyst Call or can drop down your inquiry.

The key research methodology used by DBMR Research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Reasons to Purchase this Report

  • Current and future of Global cancer biomarkers market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

  • All segmentation provided above in this report is represented at country level
  • All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)
Choose Licence Type

Enterprise, Single User

TABLE OF CONTENTS GLOBAL CANCER BIOMARKERS MARKET

1. INTRODUCTION

1.1. OVERVIEW OF THE GLOBAL CANCER BIOMARKERS MARKET
1.2. CURRENCY AND PRICING
1.3. LIMITATION
1.4. MARKETS COVERED

2 MARKET SEGMENTATION

2.1. KEY TAKEAWAYS

2.2. ARRIVING AT THE GLOBAL CANCER BIOMARKERS MARKET SIZE

2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 MARKET TIME LINE
2.2.4 MARKET GUIDE
2.2.5 COMPANY POSITIONING GRID
2.2.6 COMAPANY MARKET SHARE ANALYSIS
2.2.7 MULTIVARIATE MODELLING
2.2.8 STANDARDS OF MEASUREMENT
2.2.9 TOP TO BOTTOM ANALYSIS
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES

2.3. GLOBAL CANCER BIOMARKERS MARKET: RESEARCH SNAPSHOT

2.4. ASSUMPTIONS

3 MARKET OVERVIEW

3.1. DRIVERS

3.1.1. TECHNOLOGICAL DEVELOPMENT SUCH AS GENOME SEQUENCING
3.1.2. INCREASED PREVALENCE OF CANCER
3.1.3. INCREASED USE OF CANCER BIOMARKERS DUE TO ITS ACCURACY AND SPEED OF DIAGNOSIS
3.1.4. R&D INVESTMENTS IN DISCOVERY OF DRUGS

3.2. RESTRAINTS

3.2.1. HIGH INITIAL COST
3.2.2. WEAK REIMBURSEMENT POLICY

3.3. OPPORTUNITIES

3.3.1. GROWTH IN USE OF CANCER BIOMARKERS IN EMERGING REGIONS
3.3.2. INCREASING DEMAND OF PERSONALIZED MEDICINES AND COMPANION DIAGNOSTICS

3.4. CHALLENGES

3.4.1. HOSPITAL BUDGETS
3.4.2. INCREASING ADOPTION OF REFURBISHED INTERVENTIONAL RADIOLOGY SYSTEMS

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

5.1. VENDOR POSITIONING GRID AND INVESTMENT OPPURTUNITIES
5.2. TECHNOLOLGICAL ADVANCEMENTS
5.3. EMPIDEMIOLOGY OF VARIOUS TYPES OF CANCER
5.4. INSIGHTS ON TECHNOLOGICAL DEVELOPMENTS IN THE GLOBAL CANCER BIOMARKERS MARKET
5.5. MARKET REGULATORY SCENARIO BY COUNTRY
5.6. INTERVIEW KEY INSIGHTS

6 GLOBAL CANCER BIOMARKERS MARKET, BY TYPE

6.1. OVERVIEW
6.2. PROTEIN BIOMARKERS
6.3. GENETIC BIOMARKERS
6.4. OTHERS

7 GLOBAL CANCER BIOMARKERS MARKET, BY CANCER TYPE

7.1. OVERVIEW
7.2. BREAST CANCER
7.3. LUNG CANCER
7.4. COLORECTAL CANCER
7.5. PROSTRATE CANCER
7.6. CERVICAL CANCER
7.7. BLOOD CANCER
7.8. OTHERS

8 GLOBAL CANCER BIOMARKERS MARKET, BY CATEGORY

8.1. OVERVIEW
8.2. CANCER BIOMARKERS OF EXPOSURE
8.3. CANCER BIOMARKERS OF DISEASE

9 GLOBAL CANCER BIOMARKERS MARKET, BY BIOMOLECULE

9.1. OVERVIEW
9.2. GENETIC BIOMARKERS
9.3. EPIGENETIC BIOMARKERS
9.4. METABOLIC BIOMARKERS
9.5. PROTEOMIC BIOMARKERS
9.6. GLYCOMIC BIOMARKERS

10 GLOBAL CANCER BIOMARKERS MARKET, BY APPLICATION

10.1. OVERVIEW
10.2. DRUG DISCOVERY
10.3. DIAGNOSTICS
10.4. PERSONALIZED MEDICINE
10.5. OTHERS

11 GLOBAL CANCER BIOMARKERS MARKET, BY TECHNOLOGY

11.1. OVERVIEW

11.2. OMICS TECHNOLOGIES

11.2.1 GENOMICS
11.2.2 PROTEOMICS
11.2.3 METABOLOMICS
11.2.4 TRANSCRIPTOMICS
11.2.5 PHARMACOGENOMICS

11.3. IMAGING TECHNOLOGIES

11.4. IMMUNOASSAYS

11.2.1 IMMUNOHISTOCHEMICAL (IHC) TESTS

11.2.2 FLOW CYTOMETRY

11.2.3 CYTOGENETICS

11.2.4 BIOINFORMATICS

11.2.5 IVD MULTIVARIATE INDEX ASSAYS

12 GLOBAL CANCER BIOMARKERS MARKET, BY END-USER

12.1. OVERVIEW
12.2. HOSPITALS
12.3. CANCER DIAGNOSTIC CENTERS
12.4. CLINICS
12.5. AMBULATORY CENTERS

13 GLOBAL CANCER BIOMARKERS MARKET, BY GEOGRAPHY

13.1 COUNTRYWISE GLOBAL CANCER BIOMARKERS MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

13.1.1 NORTH AMERICA

13.1.1.1 U.S.
13.1.1.2 CANADA
13.1.1.3 MEXICO

13.1.2 EUROPE

13.1.2.1. GERMANY
13.1.2.2 FRANCE
13.1.2.3 U.K.
13.1.2.4 ITALY
13.1.2.5 SPAIN
13.1.2.6 RUSSIA
13.1.2.7 TURKEY
13.1.2.8 BELGIUM
13.1.2.9 NETHERLANDS
13.1.2.10 SWITZERLAND
13.1.2.11 REST OF EUROPE

13.1.3 ASIA-PACIFIC (APAC)

13.1.3.1 JAPAN
13.1.3.2 CHINA
13.1.3.3 SOUTH KOREA
13.1.3.4 INDIA
13.1.3.5 AUSTRALIA
13.1.3.6 SINGAPORE
13.1.3.7 THAILAND
13.1.3.8 MALAYSIA
13.1.3.9 INDONESIA
13.1.3.10 PHILIPPINES
13.1.3.11 REST OF APAC

13.1.4 SOUTH AMERICA

13.1.4.1 BRAZIL
13.1.4.2 REST OF LATIN AMERICA

13.1.5 MIDDLE EAST AND AFRICA

13.1.5.1 SAUDI ARABIA
13.1.5.2 REST OF MIDDLE EAST AND AFRICA

13.2 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

15 GLOBAL CANCER BIOMARKERS MARKET: COMPETITIVE LANDSCAPE

15.1. GLOBAL CANCER BIOMARKERS MARKET: COMPANY SHARE ANALYSIS

15.2. MERGERS & ACQUISITIONS
15.3. NEW PRODUCT DEVELOPMENT & APPROVALS
15.4. EXPANSIONS
15.5. REGULATORY CHANGES
15.6. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

16 GLOBAL CANCER BIOMARKERS MARKET, COMPANY PROFILES

16.1 ABBOTT

16.1.1 COMPANY OVERVIEW
16.1.2. FINANCIAL ANALYSIS
16.1.3. PRODUCT MATRIX
16.1.4 RECENT DEVELOPMENTS
16.1.5. DATABRIDGE ANALYSIS

16.2 BITRON HEALTHCARE

16.2.1. COMPANY OVERVIEW
16.2.2 FINANCIAL ANALYSIS
16.2.3 PRODUCT MATRIX
16.2.4. RECENT DEVELOPMENTS
16.2.5. DATABRIDGE ANALYSIS

16.3 ILLUMINA, INC.

16.3.1. COMPANY OVERVIEW
16.3.2. FINANCIAL ANALYSIS
16.3.3. PRODUCT MATRIX
16.3.4. RECENT DEVELOPMENTS
16.3.5. DATABRIDGE ANALYSIS

16.4 QIAGEN

16.4.1. COMPANY OVERVIEW
16.4.2. FINANCIAL ANALYSIS
16.4.3. PRODUCT MATRIX
16.4.4. RECENT DEVELOPMENTS
16.4.5. DATABRIDGE ANALYSIS

16.5 F. HOFFMANN-LA ROCHE LTD

16.5.1. COMPANY OVERVIEW
16.5.2. FINANCIAL ANALYSIS
16.5.3. PRODUCT MATRIX
16.5.4. RECENT DEVELOPMENTS
16.5.5. DATABRIDGE ANALYSIS

16.6 AGILENT TECHNOLOGIES

16.6.1. COMPANY OVERVIEW
16.6.2. FINANCIAL ANALYSIS
16.6.3. PRODUCT MATRIX
16.6.4. RECENT DEVELOPMENTS
16.6.5. DATABRIDGE ANALYSIS

16.7 QUEST DIAGNOSTICS INC.

16.7.1. COMPANY OVERVIEW
16.7.2. FINANCIAL ANALYSIS
16.7.3. PRODUCT MATRIX
16.7.4. RECENT DEVELOPMENTS
16.7.5. DATABRIDGE ANALYSIS

16.8 MERCK & CO. INC.

16.8.1. COMPANY OVERVIEW
16.8.2. FINANCIAL ANALYSIS
16.8.3. PRODUCT MATRIX
16.8.4. RECENT DEVELOPMENTS
16.8.5. DATABRIDGE ANALYSIS

16.9 HOLOGIC, INC.

16.9.1. COMPANY OVERVIEW
16.9.2. FINANCIAL ANALYSIS
16.9.3. PRODUCT MATRIX
16.9.4. RECENT DEVELOPMENTS
16.9.5. DATABRIDGE ANALYSIS

16.10 BD

16.10.1. COMPANY OVERVIEW
16.10.2. FINANCIAL ANALYSIS
16.10.3. PRODUCT MATRIX
16.10.4. RECENT DEVELOPMENTS
16.10.5. DATABRIDGE ANALYSIS

16.11 SINO BIOLOGICAL INC.

16.11.1. COMPANY OVERVIEW
16.11.2. FINANCIAL ANALYSIS
16.11.3. PRODUCT MATRIX
16.11.4. RECENT DEVELOPMENTS
16.11.5. DATABRIDGE ANALYSIS

16.12 THERMO FISHER SCIENTIFIC INC.

16.12.1. COMPANY OVERVIEW
16.12.2. FINANCIAL ANALYSIS
16.12.3. PRODUCT MATRIX
16.12.4. RECENT DEVELOPMENTS
16.12.5. DATABRIDGE ANALYSIS

16.13 BIOMÉRIEUX SA

16.13.1. COMPANY OVERVIEW
16.13.2. FINANCIAL ANALYSIS
16.13.3. PRODUCT MATRIX
16.13.4. RECENT DEVELOPMENTS
16.13.5. DATABRIDGE ANALYSIS

16.14 NOVARTIS AG

16.14.1. COMPANY OVERVIEW
16.14.2. FINANCIAL ANALYSIS
16.14.3. PRODUCT MATRIX
16.14.4. RECENT DEVELOPMENTS
16.14.5. DATABRIDGE ANALYSIS

16.15 MYRIAD GENETICS

16.15.1. COMPANY OVERVIEW
16.15.2. FINANCIAL ANALYSIS
16.15.3. PRODUCT MATRIX
16.15.4. RECENT DEVELOPMENTS
16.15.5. DATABRIDGE ANALYSIS

16.16 GENOMIC HEALTH

16.16.1. COMPANY OVERVIEW
16.16.2. FINANCIAL ANALYSIS
16.16.3. PRODUCT MATRIX
16.16.4. RECENT DEVELOPMENTS
16.16.5. DATABRIDGE ANALYSIS

16.17 PFIZER, INC.

16.17.1. COMPANY OVERVIEW
16.17.2. FINANCIAL ANALYSIS
16.17.3. PRODUCT MATRIX
16.17.4. RECENT DEVELOPMENTS
16.17.5. DATABRIDGE ANALYSIS

16.18 BRISTOL-MYERS SQUIBB

16.18.1. COMPANY OVERVIEW
16.18.2. FINANCIAL ANALYSIS
16.18.3. PRODUCT MATRIX
16.18.4. RECENT DEVELOPMENTS
16.18.5. DATABRIDGE ANALYSIS

16.19 EPIGENOMICS AG

16.19.1. COMPANY OVERVIEW
16.19.2. FINANCIAL ANALYSIS
16.19.3. PRODUCT MATRIX
16.19.4. RECENT DEVELOPMENTS
16.19.5. DATABRIDGE ANALYSIS

16.20 STAT BIOMEDICAL CO., LTD.

16.20.1. COMPANY OVERVIEW
16.20.2. FINANCIAL ANALYSIS
16.20.3. PRODUCT MATRIX
16.20.4. RECENT DEVELOPMENTS
16.20.5. DATABRIDGE ANALYSIS

17 APPENDIX

18 ABOUT DATA BRIDGE MARKET RESEARCH

Please fill in the below form for detailed List of Tables

Please fill in the below form for detailed List of Tables

Please fill in the below form and our sales representatives will get back to you Shortly

Please fill in the below form and our sales representatives will get back to you Shortly

`